An Oakland biotech is preparing to test a new medicine that the company says may be effective in treating a brain injury associated with playing football.

Chronic traumatic encephalopathy, brain damage associated with contact sports, and optic nerve damage caused by glaucoma and other eye conditions are among the indications for ST266, a new medication developed by Noveome Biotherapeutics Inc. Clinical trials for nasal spray administration of the anti-inflammatory agent are anticipated later this year at the University of Pennsylvania, founder and CEO William Golden said.

Neuropathologist Bennet Omalu discovered CTE in former Pittsburgh Steelers center Mike Webster in 2002 while working as a pathologist in the Allegheny County Coroner’s office. There is no treatment for the condition, which causes motor impairment, speaking and language difficulties and dementia symptoms, so athletic trainers focus instead on preventing head injuries that cause the condition.

“We have a very, very safe product,” said Mr. Golden, 65. “No adverse events.”

Advertise with us

The clinical trials will be conducted with SipNose Ltd., of Yokneam, Israel, which developed a device to deliver ST266 through the nose to protect nerves in the eye or brain. The medicine is derived from processed placental cells.

Noveome has raised about $3 million from state and county government agencies to fund a lab and product development, including most recently a $500,000 grant from the Pennsylvania Department of Health. Including federal government funding, the company has raised $114 million. Noveome has avoided venture capital investment to be able to remain in Pittsburgh after its product is marketed, Mr. Golden said, which is expected within three years.

“We’re trying to become an anchor biotech company in Pittsburgh,” Mr. Golden said, the start of a cluster of similar outfits.

Pittsburgh life sciences companies that accept venture money often have to move to Boston, Silicon Valley or other tech hubs to be closer to funding agencies.

“It is very timely and exciting to have an established Pittsburgh biotech company and an innovative Israeli company collaborating on this critical life sciences project,” Dennis Davin, secretary of the state Department of Community and Economic Development, said in a prepared statement.

Advertise with us

Noveome’s collaboration with SipNose came after Pennsylvania and the State of Israel signed an Agreement on Cooperation in Research, Development and Technological Innovation in November. The company employs 30 people, mostly in Pittsburgh.

The company was founded in 2000 as Stemnion Inc. before changing its name to Noveome in 2016. Phase one clinical trials, the first step in getting approval by the Food & Drug Administration, are designed to ascertain the safety of the medicine.

Kris B. Mamula: kmamula@post-gazette.com or 412-263-1699.